Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas
- Sponsor
- The Hospital for Sick Children
- Study ID
- NCT03054792
- Phase
- PHASE1
- Status
- Enrolling By Invitation
Conditions
- Non-Rhabdo. Soft Tissue Sarcoma
- Rhabdomyosarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- Blood Oxygen Level Dependent [BOLD] MRI — DIAGNOSTIC_TESTBOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
- Diffusion-Weighted [DW] MRI — DIAGNOSTIC_TESTDW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
- Magnetic Resonance Spectroscopy [MRS] — DIAGNOSTIC_TESTMRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
Study Details
This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.
Key Dates
- First listed
- Feb 16, 2017
- Start date
- May 1, 2017
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: BOLD- DW- MRSBlood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, MR Spectroscopy \[MRS\]
Primary Outcome Measure
Number of participants with response to therapy [ Time Frame: 1 year ]
Related Studies
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Familial Investigations of Childhood Cancer PredispositionRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesPHASE1 · Recruiting · New York Medical College · Valhalla, New York
- Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas